PUBLISHER: Grand View Research | PRODUCT CODE: 1790373
PUBLISHER: Grand View Research | PRODUCT CODE: 1790373
Cardiac Monitoring And Cardiac Rhythm Management Devices Market Summary
The global cardiac monitoring and cardiac rhythm management devices market size was estimated at USD 21.84 billion in 2024 and is projected to reach USD 32.34 billion by 2033, growing at a CAGR of 4.45% from 2025 to 2033. Increasing cardiovascular incidence is one of the key factors driving the market's growth.
According to an Oxford Academic article published in January 2025, the global age-standardized prevalence of cardiovascular disease reaches about 7,179 cases per 100,000 people, emphasize the significant and ongoing impact of heart conditions globally. Such widespread prevalence means that millions are living with diseases that require careful monitoring and timely intervention to prevent complications. This fuels demand for cardiac monitoring and cardiac rhythm management devices, which are critical for identifying abnormal heart rhythms, managing chronic heart conditions, and reducing the risk of serious cardiac events.
Increasing awareness campaigns and government-initiated screening programs for early detection of CVDs contribute to market expansion by ensuring more patients receive timely diagnosis and treatment. According to an article published by Hearst Newspapers II, LLC in June 2025, Midland Memorial Hospital, working alongside the Championship Hearts Foundation, conducts free ECG and limited echocardiogram screenings for teenagers between 14 and 18 years old. In previous events, these screenings identified severe, potentially life-threatening heart conditions, such as hypertrophic cardiomyopathy, in approximately 1 out of every 250 participants. Initiatives like this highlight the critical role of early detection in preventing sudden cardiac events among young people. They also emphasize the growing need for portable ECG devices and advanced rhythm-monitoring technologies tailored for pediatric and adolescent populations, contributing to expanding the cardiac monitoring and cardiac rhythm management devices market.
Furthermore, according to the American Heart Association, Inc. article published in November 2023, the 2023 guidelines issued by the American Heart Association (AHA), American College of Cardiology (ACC), American College of Chest Physicians (ACCP), and the Heart Rhythm Society (HRS) emphasize the importance of increasing awareness and incorporating routine screening for atrial fibrillation (AFib), especially among high-risk groups like older adults. These recommendations advocate for regular pulse and ECG screenings to facilitate early diagnosis and effective treatment. Detecting and managing AFib promptly is vital because it can substantially reduce the risk of stroke and other serious health problems. This focus on proactive screening and education drives up demand for cardiac monitoring and rhythm management devices, which are essential for identifying heart rhythm disorders and guiding proper medical care, thereby boosting market growth.
The efficiency of targeted screening programs for CVDs fuels market growth. According to Springer Nature, in June 2024,a review of cardiology reports examines the impact of screening programs. It highlights findings from multicenter studies, such as AF-SCREEN and STROKESTOP, which show that targeted screening greatly enhances the detection of CVDs, especially among older adults. The review strongly supports establishing national screening initiatives to address the growing burden of AFib-related complications, highlighting the critical role of early detection and intervention.
The technologically advanced products offered by the key players drive the market's growth. For instance, in April 2025, LifeSignals, Inc. introduced the UbiqVue 2AYe Holter System at Heart Rhythm 2025. This new Holter monitoring solution, distributed in collaboration with UltraLinQ Healthcare Solutions, is designed to streamline cardiac monitoring workflows by producing diagnostic reports far faster than traditional methods and eliminating the need to mail or physically retrieve the biosensor device.
At the heart of the UbiqVue system is the 2AYe Biosensora, a disposable, chest-worn device capable of continuously recording two-channel ECG and event data for up to five days. Data collected by the biosensor is securely encrypted and sent via a patient-facing mobile app to a cloud-based platform during the monitoring period. Once the Holter test concludes, the patient's data is quickly analyzed through cloud-based ECG analytics, substantially reducing the review time required by certified cardiac technicians and enabling physicians to access finalized reports within hours.
Global Cardiac Monitoring And Cardiac Rhythm Management Devices Market Report Segmentation
This report forecasts revenue growth and analyzes the latest trends in each sub-segments from 2021 to 2033 at the global, regional, and country levels. For this report, Grand View Research has segmented the global cardiac monitoring and cardiac rhythm management devices market report based on product, end use, and region: